2 results
Approved WMORecruiting
The aim of this study is to investigate non-inferiority of rituximab SC 336 mg to rituximab IV 200 mg.
Approved WMOPending
The purpose of the current study is to determine the feasibility of using MFGS using Cetuximab-800CW as an intraoperative margin assessment tool for penile carcinoma.